Prostate Cancer - Results from #820

A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. June 11, 2024

A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts. June 11, 2024

Surgical gestures to evaluate apical dissection of robot-assisted radical prostatectomy. June 10, 2024

International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer. June 10, 2024

Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging. June 10, 2024

Prostate Cancer Recurrence: Examining the Role of Salvage Radiotherapy Field and Risk Factors for Regional Disease Recurrence Captured on 18F-DCFPyL PET/CT. June 10, 2024

A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer. June 10, 2024

PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. June 10, 2024

Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer. June 7, 2024

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. June 7, 2024

Receipt of prostate-specific antigen test in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states. June 7, 2024

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. June 7, 2024

Natural language processing pipeline to extract prostate cancer-related information from clinical notes. June 7, 2024

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. June 6, 2024

Risk calculators for the detection of prostate cancer: a systematic review. June 6, 2024

Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer. June 6, 2024

RNASEH2B loss and PARP inhibition in advanced prostate cancer. June 6, 2024

Transperineal 3-Core Magnetic Resonance Imaging Ultrasound Fusion Targeted Plus Laterally 6-Core Systematic Biopsy in Prostate Cancer Diagnosis. June 6, 2024

Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice. June 6, 2024

PARP inhibitors in prostate cancers, is it time for combinations? June 5, 2024

Page 42 of 1438